Effect of cardiac rehabilitation on inflammatory markers

Effects of cardiac rehabilitation on C-reactive protein, neutrophil-to-lymphocyte, and platelet-to-lymphocyte ratio in unstable ischemic heart disease patients following percutaneous coronary intervention: A randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210827052304N2

Enrollment

120

Registered

2022-12-03

Start date

2018-01-01

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluating inflammatory markers in patients with unstable ischemic heart diseases after cardiac rehabilitation. Unstable angina

Interventions

Intervention 1: Intervention group: , Patients in the intervention group underwent a 12-week cardiac rehabilitation. The cardiac rehabilitation program included once-a-week supervised aerobic exercise

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All > 18 years patients with unstable ischemic heart disease (UIHD) with negative enzymes who had undergone successful percutaneous coronary intervention (PCI) Informed consent

Exclusion criteria

Exclusion criteria: Age > 70 years History of dysrhythmia History of decompensated heart failure History of coronary artery bypass graft (CABG) History of myocardial infarction Uncontrolled hypertension Uncontrolled diabetes mellitus, Physical disability History of respiratory dysfunction History of cerebrovascular diseases History of severe valvular heart diseases History of any known inflammatory diseases other than atherosclerosis Ongoing clinical infection Planned surgery within the next four months

Design outcomes

Primary

Measure	Time frame
High sensitivity CRP. Timepoint: The mentioned factor were taken at Baseline mode (ie before the discharge of patients admitted for PCI). After this time, patients in the intervention group received 12 week cardiac rehabilitation and the control group received only routine care. At the end of 12 weeks, blood samples were taken again from both groups of patients. Method of measurement: hs-CRP : hs-CRP kit by ROCHE company.;Platelet to lymphocyte ratio. Timepoint: The mentioned factor were taken at Baseline mode (ie before the discharge of patients admitted for PCI). After this time, patients in the intervention group received 12 week cardiac rehabilitations and the control group received only routine care. At the end of 12 weeks, blood samples were taken again from both groups of patients. Method of measurement: PLR : platelet count( per cubic millimeter of blood) divided by lymphocyte count ( per cubic millimeter of blood) . Cell count was performed using SYSMEX cell counter.;Neutrophil to lymphocyte ratio. Timepoint: The mentioned factor were taken at Baseline mode (ie before the discharge of patients admitted for PCI). After this time, patients in the intervention group received 12 week cardiac rehabilitations and the control group received only routine care. At the end of 12 weeks, blood samples were taken again from both groups of patients. Method of measurement: NLR : neutrophil count( per cubic millimeter of blood) divided by lymphocyte count ( per cubic millimeter of blood) - Cell count was performed using SYSMEX cell counter.	—

Measure

Time frame

High sensitivity CRP. Timepoint: The mentioned factor were taken at Baseline mode (ie before the discharge of patients admitted for PCI). After this time, patients in the intervention group received 12 week cardiac rehabilitation and the control group received only routine care. At the end of 12 weeks, blood samples were taken again from both groups of patients. Method of measurement: hs-CRP : hs-CRP kit by ROCHE company.;Platelet to lymphocyte ratio. Timepoint: The mentioned factor were taken at Baseline mode (ie before the discharge of patients admitted for PCI). After this time, patients in the intervention group received 12 week cardiac rehabilitations and the control group received only routine care. At the end of 12 weeks, blood samples were taken again from both groups of patients. Method of measurement: PLR : platelet count( per cubic millimeter of blood) divided by lymphocyte count ( per cubic millimeter of blood) . Cell count was performed using SYSMEX cell counter.;Neutrophil to lymphocyte ratio. Timepoint: The mentioned factor were taken at Baseline mode (ie before the discharge of patients admitted for PCI). After this time, patients in the intervention group received 12 week cardiac rehabilitations and the control group received only routine care. At the end of 12 weeks, blood samples were taken again from both groups of patients. Method of measurement: NLR : neutrophil count( per cubic millimeter of blood) divided by lymphocyte count ( per cubic millimeter of blood) - Cell count was performed using SYSMEX cell counter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMana Jameie

Tehran University of Medical Sciences

jameie.mana@gmail.com009888029600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026